Table 2 Characteristics of the studies analyzing CYP2E1 rs2031920 and HCC susceptibility
Author | Country | Year | Cases | Controls | HWE | Genotyping method | Virus infection | Quality score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | CC | CT | TT | Total | CC | CT | TT | Cases | Controls | ||||||
Yu | China | 1995 | 30 | 25 | 5 | 0 | 150 | 95 | 49 | 6 | Yes | PCR-RFLP | HBsAg (+), 96.7%; anti-HCV (+), 16.7% | HBsAg (+), 49.3%; anti-HCV (+), 4.0% | 7 |
Lee | Korea | 1997 | 108 | 67 | 36 | 5 | 31 | 23 | 6 | 2 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 8 |
Liu | China | 2000 | 84 | 60 | 22 | 2 | 144 | 80 | 57 | 7 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 7 |
Yu | China | 2002 | 131 | 83 | 41 | 7 | 134 | 77 | 47 | 10 | Yes | PCR-RFLP | HBsAg (+), 67.9%; anti-HCV (+), 5.2% | HBsAg (+), 15.7%; anti-HCV (+), 6.0% | 8 |
Kato | Japan | 2003 | 93 | 57 | 36 (CT + TT) | 115 | 68 | 47 (CT + TT) | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), 100% | HBsAg (+), not reported; anti-HCV (+), 0% | 7 | ||
Munaka | Japan | 2003 | 77 | 45 | 32 (CT + TT) | 138 | 89 | 49 (CT + TT) | Yes | PCR-RFLP | HBsAg (+), 17.9%; anti-HCV (+), 69.2% | HBsAg (+), 0.7%; anti-HCV (+), 7.3% | 8 | ||
Meng | China | 2003 | 21 | 1 | 19 | 1 | 50 | 36 | 14 | 0 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 6 |
Jiang | China | 2004 | 207 | 122 | 76 | 9 | 208 | 131 | 67 | 10 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 6 |
Wu | China | 2007 | 63 | 43 | 17 | 3 | 86 | 47 | 31 | 8 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 8 |
Imaizumi | Japan | 2009 | 209 | 127 | 73 | 9 | 256 | 160 | 83 | 13 | Yes | PCR-RFLP | HBsAg (+) 9.1%; anti-HCV (+), 85.6% | HBsAg (+), 2.3%; anti-HCV (+), 7.8% | 6 |
Di | China | 2013 | 95 | 80 | 15 | 0 | 97 | 84 | 13 | 0 | Yes | PCR-RFLP | HBsAg (+), not reported; anti-HCV (+), not reported | HBsAg (+), not reported; anti-HCV (+), not reported | 8 |
Ye | China | 2018 | 300 | 203 | 87 | 10 | 292 | 196 | 81 | 15 | Yes | PCR-RFLP | HBsAg (+), 85.0%; anti-HCV (+), not reported | HBsAg (+), 10.3%; anti-HCV (+), not reported | 8 |